Abstract
BackgroundUpadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA). JAK inhibitors have been associated with an increased risk of herpes zoster (HZ)...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have